Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefurulimab in pediatric AChR-positive generalized myasthenia gravis
2024-515157-17-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, open-label trial of gefurulimab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoints: Serum gefurulimab concentrations and Serum free C5 concentrations. Planned start Mar 2025; status: authorised.
02
Drugs
gefurulimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-515157-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515157-17-00.